New Methods Of Treatment Parkinson's Disease

New Methods Of Treatment Parkinson's Disease.
Parkinson's blight has no cure, but three theoretical treatments may succour patients cope with unpleasant symptoms and related problems, according to unheard of research. The research findings will be presented at the annual gathering of the American Academy of Neurology in San Diego from March 16 to 23, 2013. "Progress is being made to lengthen our use of medications, improve new medications and to treat symptoms that either we haven't been able to go into effectively or we didn't realize were problems for patients," said Dr Robert Hauser, professor of neurology and commander of the University of South Florida Parkinson's Disease and Movement Disorders Center in Tampa venapro.herbalous.com. Parkinson's disease, a degenerative wit disorder, affects more than 1 million Americans.

It destroys cheek cells in the mastermind that affirm dopamine, which helps control muscle movement. Patients participation shaking or tremors, slowness of movement, equilibrium problems and a stiffness or rigidity in arms and legs. In one study, Hauser evaluated the knock out droxidopa, which is not yet approved for use in the United States, to remedy patients who experience a rapid destruction in blood pressure when they stand up, which causes light-headedness and dizziness muscle or chest or thhai kashe banaye. About one-fifth of Parkinson's patients have this problem, which is due to a damp squib of the autonomic troubled system to release enough of the hormone norepinephrine when state changes.

Hauser studied 225 people with this blood-pressure problem, assigning half to a placebo classify and half to take droxidopa for 10 weeks. The antidepressant changes into norepinephrine in the body. Those on the drug had a two-fold decline in dizziness and lightheadedness compared to the placebo group hghser.com. They had fewer falls, too, although it was not a statistically significant decline.

In a subscribe to study, Hauser assessed 420 patients who sagacious a continuously "wearing off" of the Parkinson's c physic levodopa, during which their symptoms didn't respond to the drug. He compared those who took diverse doses of a new drug called tozadenant, which is not yet approved, with those who took a placebo.

All still took the levodopa. At the and drop of the study, the patients had an standard of six hours of "off time" a daylight when symptoms reappeared. After 12 weeks, those on a 120-milligram or 180-milligram prescribe of tozadenant had about an hour less of "off time" each hour than they had at the start of the study.

Tozadenant, which works on intellectual receptors thought to regulate motor function, merits further observe in future trials. In another study, Hauser looked at 321 patients with betimes stage Parkinson's whose symptoms weren't handled well by a panacea called a dopamine agonist, typically the at the outset drug prescribed for Parkinson's patients. During the 18-week study, Hauser assigned them to turn to either their usual medicine plus an add-on treatment called rasagiline (brand name Azilect) or their usual nostrum and a placebo.

Azilect is approved for use in patients with early stage contagion as a single therapy or as an add-on to levodopa but not yet as an add-on to dopamine agonists. Those taking the Azilect - but not those taking the placebo - improved by 2,4 points on a bar Parkinson's disorder rating scale. Costs of the still unapproved drugs are not known.

Azilect costs about $200 monthly at the 1-milligram quotidian quantity used in the study. Each of the studies was funded by the pharmaceutical companionship making the particular drug: Chelsea Therapeutics paid for the blood-pressure study; Biotie Therapies Inc, supported the "wearing-off" study; and Teva Pharmaceutical Industries sponsored the Azilect study. Hauser is a doctor for all three companies.

Most exciting of the three studies is the use of droxidopa to avoid dizziness and fainting, said Dr Michael Okun, governmental medical number one of the National Parkinson Foundation and steersman of the University of Florida Center for Movement Disorders and Neurorestoration. Drugs are already nearby to wine and dine the problem, and compression stockings are also often recommended.

Even so, "having another treat in that arena is going to help a lot of people". The paraphernalia of the other two treatments are more modest who is also a neurology professor. Additional studies will assistant determine how noteworthy the effects are in real life herbalms com. Findings presented at medical meetings should be considered prior until published in a peer-reviewed medical journal.